We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Israeli generic firm Teva Pharmaceutical is objecting to what it contends is pressure from U.S. trade officials that Israel adopt a 10-year data exclusivity period for drugs — a period twice as long as the exclusivity period in the U.S.
Eon Labs on April 22 reported net sales of $104 million in the quarter, an increase of more than 47 percent over the $70 million reported in the same period last year.
Teva Pharmaceutical and Alpharma have agreed to share a portion of Alpharma’s 180-day market exclusivity period for a version of Pfizer’s epilepsy drug Neurontin (gabapentin) — a move that could expedite generic competition on the profitable drug, according to an analyst.
Lawmakers in Canada have approved a widely watched drug export bill that would let Canadian generic drug firms break patents on brand products exported to poor countries.
Drugmaker Roche has announced it will not enforce patents on its drug products sold in the world's least-developed countries -- a move that frees generic firms to supply those markets with versions of Roche products.
Drugmakers — especially brand companies — have several options for minimizing the effects of changes in Rx drug importation policy on U.S. pharmaceutical prices, including gaining FDA and foreign-government cooperation in limiting the trade practice, according to a report from the Congressional Budget Office (CBO).
Pfizer last week became the first major drugmaker to announce it is partnering with a major healthcare company in offering a discount card under the new Medicare program set to kick off in June.
The FTC has asked for more information about Genzyme’s plans to acquire Ilex Oncology, thus extending the time the agency has to review the planned transaction for potential antitrust complications, the two companies announced last week.
Last week’s announcement that French drugmaker Aventis’ was accepting Sanofi-Synthelabo’s improved stock-and-cash bid is part of a larger market trend being driven by increasing concern over pricing issues, according to industry analysts.